1. Introduction

cancers

Cancers

cancers

2072-6694

MDPI

10.3390/cancers5010027

cancers-05-00027

Review

Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors

Schaffner

Florence

Ray

Anne Marie

Dontenwill

Monique

UMR 7213 CNRS, Laboratoire de Biophotonique et Pharmacologie, Tumoral signaling and therapeutic targets, Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch, France; E-Mails: florence.schaffner@unistra.fr (F.S.); amray@unistra.fr (A.M.R.)

* Author to whom correspondence should be addressed; E-Mail: monique.dontenwill@unistra.fr; Tel.: +33-3688-54267; Fax: +33-3688-54313.

15 01 2013

03 2013

5 1 27 47 05 12 2012 09 01 2013 11 01 2013

2013

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors.

α5β1 integrin fibronectin receptor solid tumors angiogenesis antagonists

1. Introduction

In recent years, integrins have attracted increasing interest for their potential to act as tumor therapeutic targets [1,2]. First recognized as cell adhesion molecules and receptors for the extracellular matrix (ECM), it is now widely acknowledged that integrins act as true receptors regulating intracellular signaling and cellular responses including migration, proliferation and differentiation [3]. Integrins are αβ protein heterodimers whose non covalent association defines the specificity of adhesion to particular components of the ECM or other proteins (immunoglobulin superfamily molecules, plasma proteins, VCAM1, etc.). In mammals, 18 α subunits and eight β subunits form a large family of about 24 αβ integrins, which bind to tissue and organ specific ligands. Regulating the crosstalk between cells and their surrounding microenvironment, integrins are particularly relevant in different key aspects of tumor progression. Depending on the tumor types, the expression of specific integrins differs between tumoral tissues and their corresponding healthy tissues. Integrins are overexpressed in cancer cells impacting proliferation, survival, resistance to therapies and tumor recurrence. In addition, an important role in tumor angiogenesis has been highlighted for several integrins including α5β1 and αvβ3/β5. Their overexpression on neo-vessels during the tumor angiogenic switch led to the suggestion of new anti-angiogenic therapies [4]. Cilengitide, a specific antagonist for αvβ3/β5 integrins is currently in clinical trials for the treatment of different tumors as for example the highly vascularized brain tumor glioblastoma [5]. Different recent reviews have already summarized the current knowledge about integrin structure, activation and signaling as well as integrin implication as therapeutic targets in cancer and/or angiogenesis [2,3,4,6,7,8,9]. The goal of this review is to focus on α5β1 integrin, also called the fibronectin receptor, as an emerging therapeutic target in different solid tumors. The role of α5β1 integrin in cancer has been somewhat controversial with data suggesting tumor suppressive effects while others are in favor of a protumoral behavior. In the last decade, the relationship between α5β1 integrin expression on tumors and patient survival has become increasingly recognized in several cancers. In this article we provide an overview of the implication of α5β1 integrin in tumor angiogenesis, and solid tumor aggressiveness and we list the currently available α5β1 integrin antagonists.

2. Generalities on α5β1 Integrin

Integrins are composed of an extracellular domain, a transmembrane domain and a short cytoplasmic tail. The α subunit extracellular domain has a 7-bladed β propeller connected to a thigh and two calf domains. In addition nine of the α subunits have an I domain that contains the metal ion-dependent adherent site (MIDAS), crucial for ligand binding [10]. The α subunit is responsible for the high specificity of α5β1 integrin for fibronectin. The combination of a primary interaction with the RGD site with a secondary interaction with the synergy site of fibronectin ensures both high affinity and specificity of α5β1 integrin for fibronectin [11,12]. A recent crystallography structure of α5β1 integrin in complex with a RGD-peptide has indicated that interaction of this integrin with the synergy site comes from the residue Asp 154 in the α5 subunit and also that Ca²⁺ is an important cation for fibronectin binding [13]. The β subunit extracellular part is composed of a hybrid domain, a betaI domain (with a MIDAS structure), a plexin/semaphorin/integrin domain and four EGF like domains [14].

Crystal structures have revealed that β3 integrins occur in three possible states: low, intermediate and high affinity for its ligand [15,16]. Activation of integrin either by binding to its ligand (outside-in signaling) or by binding of an activator protein like talin to its cytoplasmic tail (inside-out signaling) result in a change in conformation from a bent (low affinity) to an extended (high affinity). At the proximal site of the transmembrane domain GFFKR, residues, extremely conserved in the α subunit, and hydrophobic membrane-proximal residues in the β subunit, are involved in releasing the integrin from an inactive to an active conformation, with unbound cytoplasmic tails available for signal transduction [7,17]. Integrins do not have enzymatic activity therefore signal transduction is performed by proteins recruited to the cytoplasmic tail such as FAK, src, and talin [1,7]. Length and intensity of the signal is regulated in part by specific negative regulators proteins such as ICAP1 or sharpin [18]. Integrin α5β1 has specific regulator such as nischarin [19] and GIPC1 [20]. In addition to the recruitment of signaling inhibitors, integrin trafficking can regulate signaling [21]. After activation, α5β1 integrin can either be ubiquitinated and degraded in lysosome or get recycled rapidly to the plasma membrane via the early endosome pathway [21]. Ubiquitination and degradation in lysosome of α5β1 integrin is important for proper fibroblast migration on fibronectin [22]. Integrins can also be internalized via clathrin dependent or independent pathway [21]. Caveolar internalization of α5β1 integrin and fibronectin promotes matrix turnover [23]. Interestingly, it seems that caveolin-1 is capable of internalizing α5β1 integrin without fibronectin, thereby regulating the amount of the fibronectin receptor available on the cell surface. This type of regulation was also shown on endothelial cell with internalization of active or inactive α5β1 integrin by two different pathways [20]. Rapid recycling of β1 integrin to the plasma membrane through early endosome is regulated by Rab5-related GTPase Rab21 binding to a region close to the GFFKR motif [24]. Other small GTPase protein regulates α5β1 integrin like Rab25 that promotes invasion in cancer cells [25,26,27]. Recent data also point to a role of α5β1 integrin in mechanosensing [28,29]. In response to mechanical forces, α5β1 integrin switches between relaxed and tensioned states which allow strong adhesion and downstream signals [30,31]. The synergy site in fibronectin is required to form the tensioned bonds although the relaxed bonds only involve the RGD site [31]. Mechanical stimulation of α5β1 integrin enhances cancer cell invasion [32,33]. In summary, integrin bidirectional signaling regulates several processes such as migration, invasion, proliferation and survival specific to each cell types and is a major regulator of cancer progression which will be discussed next [1,6,8].

3. Integrin α5β1 and Angiogenesis

Angiogenesis is a key physiological and pathological process that is regulated in part by integrins. Integrins are expressed by endothelial cells, smooth muscle cells and cellular components of the blood such as platelets, monocytes, lymphocytes etc. for example [4]. Among the large integrin family, α4, α5, αv or β1 integrin subunits were shown to be required for vasculo- and angiogenesis during development [34,35,36]. Yet, each of these integrins have specific function: α4 knock out mice display an abnormal retention of hematopoietic stem cells in the bone marrow niche and cardiac defect, αv knock out mice show predominantly hemorrhage in the brain and intestine resulting in death from mid-gestation to perinatal, and β1 knock out specifically in endothelial cells resulting in the most severe phenotype with vascular remodeling defects caused by adhesion and migration alteration and reduced survival of endothelial cells. Homozygous deletion of α5 integrin subunit results in embryonic death at around E 10.5 due to defects in posterior trunk development (defects in neural tube and somites), and angiogenesis [37,38]. The α5 null embryos and the extraembryonic vessels display defects resulting in leakage of blood cells. Angiogenesis abnormalities are also observed inmice deficient in fibronectin, the major ligand for α5β1 integrin, although lethality occurs earlier at E9.5 [39]. To further understand the mechanism regulated by α5 integrin subunit in angiogenesis, conditional knock out were designed where α5^flox/flox mice were crossed with Tie2-Cre mice. The resulting mice do not express a5 integrin subunit on endothelial and hematopoietic cells. Surprisingly the embryos developed normally and do not harbor angiogenesis defects [40]. Analysis of adhesion of α5 null endothelial cells shows that αv is present to focal adhesion points and therefore compensates for the lack of α5. Double knock out of α5 and αv in endothelial cells results in abnormal vessel remodeling and heart defects in most of the embryos by E14.5. These results highlight the importance of specific integrins in developmental angiogenesis but also that compensation mechanisms by other integrins exist in order to complete angiogenesis. These mechanisms are not only observed during development but also for example in adult hypoxic brain endothelial cells [41].The compensation mechanisms may play crucial role and should be taken into consideration when analyzing the results of integrin targeting therapy.

In addition to its direct role in angiogenesis, integrin α5β1 also regulates angiogenic signals by binding with different partner such as endostatin [42], VEGFR-1 [43], Angiopoietin-2 and Tie-2 [44]. Interestingly, mature vessels present very low level of α5 integrin subunit (with the exception of hepatic sinusoid and high-endothelial venules in lymph nodes) whereas tumor vasculature or neovessels in the cornea express high level of α5 [45,46,47,48]. Injection of a specific monoclonal anti-α5 antibody in several murine cancer models shows that α5 integrin subunitis expressed on the luminal side of the tumor vasculature and thereby directly accessible for potential anti-α5 agents [49]. Integrin subunit α5 expression in endothelial cells is regulated by several angiogenic factors such as FGF, TNFα or IL8, but not VEGF [45]. In turn, activation of α5β1 on endothelial cells by attachment to fibronectin results in the transcription of a gene repertoire related to angiogenesis (HB-EGF, IL8, CXCL1), adhesion (VCAM, E-selectin), signal transduction (RICK, NFκb) and coagulation (TF) [50]. Once expressed, α5 integrin subunit promotes survival signals in angiogenic endothelial cells and blocks apoptotic signals independently of attachment to matrix in vitro and in vivo [51]. Therefore, blocking α5 integrin subunit with a small peptide or an antibody results in anti-angiogenic effects and reduced tumor growth by integrin-mediated death pathway [45,52,53]. Due to its unambiguous role in angiogenesis, α5β1 integrin has become a target for anti-angiogenesis therapy.

4. Integrin α5β1 in Solid Tumors 4.1. Colon Tumors

The controversy about α5β1 integrin as a tumor suppressor rather than a protumoral integrin mainly arose from data obtained in a colon cancer cell line, HT29. Studies showed that de novo expression of α5 integrin subunit in HT29 cells results in cell growth arrest in vitro and decreased tumorigenicity in vivo. Cell growth arrest was reversed by ligation of α5β1 integrin to fibronectin [54]. Interestingly, α5β1-expressing HT29 cells were shown to resist to serum deprivation-induced apoptosis [55]. The tumor suppressive function of α5β1 integrin in HT29 cells was confirmed in another study [56] and a strong inhibitory action of this integrin on lung colonization and metastasis was also reported [57]. These results were challenged when subgroups of colon cancer cell lines were examined according to their differentiation status [58]. It was shown that integrin α5β1 level was increased in the poorly differentiated group in relationship with an increased capacity to form tumors in nude mice [59]. In accordance with these results, three well-established colon cancer cell lines, KM20, KM12C and KML4A, treated with an anti-α5 integrin inhibitory antibody, increased their apoptosis rate [60]. It was recently found that 19% of colon carcinoma, over 94 tumors examined, expressed α5β1 integrin at the protein level and in these tumors the labeling concerned only a fraction of neoplastic epithelial cells [61]. Interestingly, acquisition of α5β1 integrin was correlated with ADAM-15 down-regulation and poor prognosis [61]. In line with this, hypoxia was shown to increase α5 integrin subunit at the mRNA level and this increase was more prominent in Duke stage C and D patients than in Duke stage A and B patients suggesting that the transcription increases along with the progression of colon cancer [62]. Upregulation of α5 integrin subunit gene transcription in colon cancer cells is under the control of PTHrP [63] or ZEB2 [64] and leads to an upregulation of cell invasion during epithelial-mesenchymal transition. Activation of α5β1 integrin and corresponding signaling pathways by P-selectin and the human carcinoembryonic antigen (CEA) was also reported in colon carcinoma cells [65,66]. Suppression of α5β1 integrin activity by lunasin, a peptide isolated from soybean and having an RGD motif, potentiates the effect of oxaliplatin thus preventing outgrowth of colon cancer metastasis [67].

4.2. Ovarian Tumors

Peritoneal dissemination is an important step in ovarian cancer progression to invasion and metastasis. It was first reported that fibronectin secreted by peritoneal tissue activates α5β1 integrin on ovarian cancer cells to stimulate their invasiveness through an increase of MMP-9 activity [68]. α5β1 integrin regulates the formation of ovarian carcinoma multicellular spheroids, an in vitro model of micrometastasis [69], and partially mediates adhesion to mesothelial cell monolayer of patient-derived ascites spheroids [70]. Many human ovarian cancer cell lines express α5β1 integrin and their binding to mouse peritoneal wall preparation was impaired specifically by anti α5β1 integrin antibodies or endostatin which is a ligand for α5β1 integrin [71,72]. Kallikrein-related peptidases (KLK) are serine proteases often upregulated in ovarian carcinoma. KLK7 overexpression correlates with formation of large compact spheroids, chemoresistance and poor outcome in clinical settings. Interestingly enhanced expression of KLK7 in ovarian cancer cell lines and clinical samples was associated with enhanced expression of α5β1 integrin [73] suggesting that α5β1 integrin participates to the poor outcome of patients. The hypothesis of α5β1 integrin as a prognostic marker in ovarian tumors is confirmed by other data including large cohorts of patients [74,75]. In one of this study [74], α5β1 integrin expression was inversely correlated with E-cadherin expression and was shown to be implicated in adhesion of tumor cells to the peritoneal cavity and metastasis. Inhibition of α5β1 integrin by specific antibodies led to the suppression of intra-peritoneal tumor spread and increased survival in two xenograft models of ovarian cancer. In fact fibronectin/α5β1 integrin interaction on ovarian cancer cells activates the oncogene cMet and provides key mitogenic-signalling pathways to the cells [76]. Adrenomedullin also upregulates α5β1 integrin in ovarian tumors and patients with high adrenomedullin expression showed a higher incidence of metastasis and poor outcomes, indirectly further suggesting a role of α5β1 integrin in the aggressiveness of ovarian tumors [77]. An overview of integrin inhibitors as therapeutic agents for ovarian cancer has been published very recently [78].

4.3. Breast Tumors

Similarly to what was shown in colon cancer cells, the first data concerning α5β1 integrin in breast tumor cells were in favor of its tumor suppressive effect. It was reported that treatment of the highly invasive breast carcinoma cell line MDA-MB-435 (which has been further classified as a melanoma cell line) with Maspin suppressed their invasive phenotype through an increased expression of α5β1 integrin at the mRNA and protein level [79]. Subsequent data however challenged this view as they demonstrated a proinvasive role of α5β1 integrin in breast cancer cells [80,81,82]. The oncogene ERBB2, strongly associated with metastatic disease and poor prognosis, drives the transcriptional upregulation of α5β1 integrin in mammary adenocarcinoma promoting tumor cell survival under adverse conditions and invasive capacity [80,83]. In a subset of breast cancers, overexpression of Steroid Receptor Coactivator-1 (SRC-1) was associated with an upregulation of α5β1 integrin and promotion of α5β1 integrin-dependent cell adhesion and migration [84]. Inverse relationship between α5β1 integrin expression and tumor suppressors expression such as nischarin [85], metastasis suppressors such as Nm23 [86] or epithelial cell-cell adhesion marker such as E-cadherin [87] were reported and associated with impact on breast cell tumorigenic potential. Loss of E-cadherin was also achieved through stimulation of breast cancer cells by angiopoietin-2 which stimulated cell migration through an α5β1 integrin-dependent way [88]. Data also showed that α5β1 integrin controls invasion of breast cancer cells by modulation of MMP-1 [81] and MMP-2 collagenase activity [89]. α5 integrin subunit mRNA was weakly expressed in normal tissues and more strongly expressed in breast cancer specimens [90] and elevated α5 integrin subunit gene expression was associated with decreased long term survival in one cohort of patients with breast cancer [91] but not in two other cohorts [92]. Interestingly, while α5 integrin subunit was proposed to be positively involved in lung metastasis of breast tumors in humans [85], the opposite effect was described for mouse breast tumor cells [93]. Finally, radiotherapy was shown to increase α5β1 integrin expression level in 3D culture breast tumor cells and combined cell treatment with ionizing radiation and antagonists of α5β1 integrin triggered apoptosis [91].

4.4. Lung Tumors

Tobacco is the major risk factor for lung tumors. The main tobacco alkaloid nicotine stimulates lung cancer cell proliferation by the induction of fibronectin that led to activation of the α5β1 integrin. In non small cell lung cancer, α5β1 integrin overexpression at the mRNA [94,95] or protein [96,97] level was negatively associated with patient survival. Interestingly, α5β1 integrin expression could differentiate between adenocarcinoma and squamous cell carcinoma of the lung [94]. α5β1 integrin expression was more frequent in tumors with lymph node metastasis than in those without metastasis [96]. Fibronectin-α5β1 integrin signaling has been studied and implicated in lung cancer progression [98,99,100] and reviewed in [101]. The PI3K/AKT/mTOR pathway is a key mediator of fibronectin-integrin effects on proliferation [99]. Extracellular matrix proteins including fibronectin were shown to protect lung cancer cells from apoptosis through β1 integrin activation [102,103,104,105] thus explaining drug resistance of lung cancer cells.

4.5. Glioma

The α5β1 integrin is expressed at significantly higher level in glioblastoma (the most aggressive glioma) than in adjacent normal brain tissue suggesting that it might play a role in the development or the progression of glioma [106]. α5β1 integrin is commonly expressed in a perinecrotic or perivascular pattern in glioblastoma [107]. α5 integrin subunit mRNA level is under the control of the transcription factor ETS-1 and its expression is related to the grade of glioma, with the highest expression in glioblastoma [108]. We [109,110] and others [111] confirmed recently these data in larger cohorts of patients and showed that a high expression of α5β1 integrin is associated to a worse prognostic for patients with glioma. We also demonstrated that α5β1 integrin expression is under the negative control of caveolin-1 and positive control of TGFβR in a subset of glioma tumors [110,112]. By the use of specific non peptidic antagonists of α5β1 integrin, its role in proliferation, migration, invasion and resistance to chemotherapy was highlighted in different glioma cell lines [109,113,114]. Interaction of MMP-2 with α5β1 integrin was shown to regulate the IL-6/STAT3 survival signaling in glioma [115]. The expression of the DNA repair protein, O6-Methylguanine-DNA Methyltransferase (MGMT), was inversely related to invasion capacity of glioma and to α5β1 integrin expression [116].

4.6. Melanoma

Malignant melanoma has a high metastatic potential. A role of α5β1 integrin in promoting melanoma metastasis through an increase in cell adhesion to fibronectin and protection against apoptosis was reported [117]. Recently, evidence that α5β1 integrin has a crucial role in melanoma metastasis confirmed this hypothesis. It was shown that α5 integrin subunit up-regulation was under the control of survivin [118] or controlled by the interaction between caveolin 1 and Rho-GTPases [119]. Curiously, the specific uveal melanoma seems to be one of the cases where α5β1 integrin expression negatively impacts on tumorigenicity. High aggressiveness of uveal melanoma cells is dependent on the loss of α5β1 integrin at the cell surface [120,121,122]. However, restoration of α5β1 integrin expression in high tumorigenic cells increased the cell resistance to stress in vitro and growth properties in vivo [121] which appears somewhat paradoxical. It has been proposed that the effect of α5β1 integrin on cell tumorigenicity depends on the endogenous expression of fibronectin by the tumoral cells.

5. Integrin α5β1 Antagonists

The search for specific α5β1 integrin antagonists has increased these last years. They are developed to understand the integrin pathophysiological behaviour in preclinical studies on endothelial and tumoral cells but also as therapeutic agents in the clinic [2]. As α5β1 integrin has been largely described as an unambiguous pro-angiogenic integrin, these antagonists are generally presented as potential anti-angiogenic agents. Three main classes of antagonists are described at the time, specific antibodies, small peptides or small non peptidic RGD-like molecules.

5.1. Antibodies

An α5β1 function-blocking murine antibody, IIA1, was used in preclinical studies [74,91]. It was able to inhibit in vitro invasion of ovarian tumor cells into Matrigel and tumor cell adhesion to mesothelial cells; it decreased the number and the size of intra-abdominal metastases and increased the survival of mice [74]. This inhibitory antibody also induced apoptosis of breast cancer cells in 3D culture conditions [91]. A chimeric humanised version of IIA1 antibody was generated, named volociximab (developed first by PDL Biopharma, Fremont, CA, USA), with similar affinity for α5β1 integrin and similar activity for blocking integrin adhesion to fibronectin than IIA1 [123]. Volociximab is a potent inhibitor of in vitro model of angiogenesis by inducing apoptosis of actively proliferating but not resting endothelial cells. It reduced vessel density and tumor growth in carcinoma xenografted in rabbits [123,124]. Results of volociximab in clinical assays have been reviewed recently in [125]. Volociximab has been shown to be safe and tolerable in phase I studies [126,127] in patients with different solid tumors. Reported adverse effects included constitutional symptoms, gastrointestinal symptoms, headache, edema and hypertension. Although α5β1 integrin is expressed on normal blood monocytes, no clinically apparent infectious complications were observed. A phase II clinical trial has shown that in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer, weekly monotherapy with volociximab was well tolerated but without efficacy on these particular population of patients [128]. In patients with refractory or relapsed metastasic clear cell renal carcinoma, volociximab led to stable disease in 80% of patients [129].

A dual functional monoclonal antibody, PF-04605412, has been developed by Pfizer. This antibody targets α5β1 integrin and was engineered to elicit potent antibody-dependent cellular toxicity [130]. Preclinical studies showed that PF-04605412 potently inhibited α5β1 integrin mediated intracellular signalling, cell adhesion, migration and angiogenesis. In animal studies, it displayed robust anti-tumor efficacy correlated with α5 integrin subunit expression, macrophages and natural killer cells infiltration [130]. A clinical trial phase I is currently underway in solid tumors refractory to available therapies.

5.2. RGD-like Molecules

The RGD motif of fibronectin is recognised by at least three main integrins: α5β1, αvβ3 and αIIbβ3. The challenge of these last ten years has been to design antagonists with enhanced selectivity for each of these integrins.

The first selective non peptidic antagonist for α5β1 integrin was SJ749 (compound 20 in [131]). SJ749 blocked efficiently α5 integrin-expressing HT29 cell adhesion to fibronectin and not to other ECM ligand. It also blocked α5β1 integrin function in chick embryo and murine models of angiogenesis acting as a potent inhibitor of tumor growth and tumor-induced angiogenesis [45]. We described that SJ749 potently inhibited the proliferation of glioma cell lines dependently of α5β1 integrin expression level [112,114] and that SJ749 sensitized glioma cells to chemotherapy by modulating the p53 pathway [113].

SJ749 was used in docking experiments to build a 3D model of the α5β1 integrin with the αvβ3 integrin crystal structure as a model [132]. Based on the characteristics of SJ749 binding site and SAR analysis, analogs of SJ749 [132] or original compounds [133,134,135] were designed by the group of H. Kessler (München, Germany) and tested for their integrin affinities. Compounds with high affinity and selectivity for α5β1 integrin were found by these strategies. Few data concerning the biological activities of such compounds are available to date. We evaluated the effects of one of these compounds, K34c, on glioma cell lines. We demonstrated that K34c affected the survival of glioma cells as well as their resistance to chemotherapies [110,113].

New selective small non peptidic α5β1 integrin antagonists were described by Jerini AG (Berlin, Germany) [136]. Compounds were mainly tested in pathological models of neovascularization where α5β1 integrin plays a crucial role [137,138,139,140,141]. One of them, JSM6427, was shown to attenuate glioma growth [141]. Interestingly, new orally available α5β1 integrin antagonists were described recently by this pharmaceutical group [142,143]. Other small non peptidic molecules were synthesized by AstraZeneca and showed some selectivity for α5β1 integrin compared to αvβ3 integrin [144,145].

5.3. Non RGD-like Peptides

Sequences outside of the RGD site are required to allow full adhesion of α5β1 integrin to fibronectin. Of particular interest is the sequence Pro-His-Ser-Arg-Asn (PHSRN) in the 9th type III repeat of fibronectin also called the “synergy site”. PHSRN peptide induced invasion of prostate tumor cells by inducing MMP-1 [146,147] and stimulation of angiogenesis [148] which was inhibited by the competitive inhibitor PHSCN peptide. The acetylated amidated PHSCN peptide was even more potent than PHSCN peptide [146], and was developed by Attenuon LLC (San Diego, CA, USA) under the name ATN-161. ATN-161 treatment blocks prostate tumor recurrence, metastasis and micrometastasis [149], reduces colorectal liver metastasis and improves survival when given in addition with chemotherapy [150], and blocks breast cancer growth and metastasis [151] in preclinical mouse models. Targeting α5β1 integrin with ATN-161 in combination with radiotherapy enhanced apoptosis of breast cancer cells grown in 3D culture [91]. ATN-161 proved also efficient to block choroidal neovascularisation [152]. Phase I trial of ATN-161 indicated that it was well tolerated in patients with solid tumors and that one third of patients manifested prolonged stable disease. No side effects emerged or became worse with continued chronic dosing of ATN-161 [153]. Recently, PHSCN dendrimers were synthesized and shown to be more potent than the initial peptide for inhibiting α5β1 integrin-mediated MMP-1 secretion in vitro and for inhibiting human prostate cancer cell invasion, extravasion and lung metastasis in vivo [154]. Similar results were reported on human breast cancer cells [155].

6. Conclusions

The critical role of α5β1 integrin in physiological angiogenesis and development has been recognized for over two decades. More recent are the data implicating α5β1 integrin in pathophysiological/tumoral neoangiogenesis. Even more recently, its role as a prognostic and diagnostic marker has been highlighted in several solid tumors. The relationship between high expression of α5β1 integrin in subpopulation of patients with solid tumor and a poor prognosis for these patients suggest its implication in resistance to conventional therapies. As shown above, α5β1 integrin is implicated in different aspects of tumor progression and appears particularly overexpressed in the most aggressive tumor grades. Ways to modulate positively the α5β1 integrin expression also appear multiple and certainly tissue dependent. Its participation in tumor angiogenesis and tumoral cell migration and adhesion to metastasis niches as well as its effects on therapy resistance make it a pertinent therapeutic target for the future. Several antagonists are being tested with some already reaching the clinic. Targeting α5β1 integrin appeared safe for the patients in the few clinical trials reported so far. To date, efforts have not focused on α5β1 integrin antagonists but data summarized here support the notion that they will play an increasing role in human therapy. The recent elucidation of the crystal structure of α5β1 integrin ectodomain will certainly help to define more potent and specific antagonists. The goal for the future will be to define clear molecular biomarkers to support the proposition of subpopulations of patients potentially sensitive to a targeted therapy against α5β1 integrin.

Aknowledgements

Work in the author’s laboratory is supported by the CNRS, the University of Strasbourg, the Ligue Contre le Cancer (Comité du Grand Est), Alsace contre le Cancer, the Fondation ARC pour la Recherche sur le Cancer. F. Schaffner is a recipient of a postdoctoral fellow from the Ligue Nationale contre le Cancer. AM Ray is a recipient of a predoctoral fellow from the Ministère de la Recherche (France) and from the Ligue Nationale contre le Cancer.

Conflict of Interests

The authors declare no conflict of interest.

References 1.

Desgrosellier

J.S.

Cheresh

D.A.

Integrins in cancer: Biological implications and therapeutic opportunities

Nat. Rev. Cancer 2010 10 9 22

10.1038/nrc2748

Goodman

S.L.

Picard

Integrins as therapeutic targets

Trends Pharmacol. Sci. 2012 33 405 412

10.1016/j.tips.2012.04.002

Aoudjit

Vuori

Integrin signaling in cancer cell survival and chemoresistance

Chemother. Res. Pract. 2012 2012 283181

22567280

Avraamides

C.J.

Garmy-Susini

Varner

J.A.

Integrins in angiogenesis and lymphangiogenesis

Nat. Rev. Cancer 2008 8 604 617

10.1038/nrc2353

Chamberlain

M.C.

Cloughsey

Reardon

D.A.

Wen

P.Y.

A novel treatment for glioblastoma: Integrin inhibition

Expert Rev. Neurother. 2012 12 421 435

10.1586/ern.11.188

Campbell

I.D.

Humphries

M.J.

Integrin structure, activation, and interactions

Cold Spring Harb. Perspect. Biol. 2011

10.1101/cshperspect.a004994

Kim

Ginsberg

M.H.

Regulation of integrin activation

Annu. Rev. Cell. Dev. Biol. 2011 27 321 345

10.1146/annurev-cellbio-100109-104104

Luo

B.H.

Integrin bi-directional signaling across the plasma membrane

J. Cell. Physiol. 2013 228 306 312

10.1002/jcp.24154

Cox

Brennan

Moran

Integrins as therapeutic targets: Lessons and opportunities

Nat. Rev. Drug Discov. 2010 9 804 820

10.1038/nrd3266

20885411

10.

Lee

J.O.

Bankston

L.A.

Arnaout

M.A.

Liddington

R.C.

Two conformations of the integrin A-domain (I-domain): A pathway for activation?

Structure 1995 3 1333 1340

10.1016/S0969-2126(01)00271-4

11.

Aota

Nomizu

Yamada

K.M.

The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function

J. Biol. Chem. 1994 269 24756 24761

7929152

12.

Obara

Kang

M.S.

Yamada

K.M.

Site-directed mutagenesis of the cell-binding domain of human fibronectin: Separable, synergistic sites mediate adhesive function

Cell 1988 53 649 657

3286012

13.

Nagae

Mihara

Nogi

Sugita

Takagi

Crystal structure of alpha5beta1 integrin ectodomain: Atomic details of the fibronectin receptor

J. Cell Biol. 2012 197 131 140

10.1083/jcb.201111077

14.

Barczyk

Carracedo

Gullberg

Integrins

Cell Tissue Res. 2010 339 269 280

10.1007/s00441-009-0834-6

15.

Xiong

J.P.

Stehle

Diefenbach

Zhang

Dunker

Scott

D.L.

Joachimiak

Goodman

S.L.

Arnaout

M.A.

Crystal structure of the extracellular segment of integrin alpha Vbeta3

Science 2001 294 339 345

10.1126/science.1064535

11546839

16.

Lau

T.L.

Kim

Ginsberg

M.H.

Ulmer

T.S.

The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling

EMBO. J. 2009 28 1351 1361

10.1038/emboj.2009.63

17.

Shattil

S.J.

Kim

Ginsberg

M.H.

The final steps of integrin activation: The end game

Nat. Rev. Mol. Cell Biol. 2010 11 288 300

10.1038/nrm2871

18.

Pouwels

Nevo

Pellinen

Ylanne

Ivaska

Negative regulators of integrin activity

J. Cell. Sci. 2012 125 3271 3280

10.1242/jcs.093641

19.

Alahari

S.K.

Nasrallah

A membrane proximal region of the integrin alpha5 subunit is important for its interaction with nischarin

Biochem. J. 2004 377 449 457

10.1042/BJ20030411

20.

Valdembri

Caswell

P.T.

Anderson

K.I.

Schwarz

J.P.

Konig

Astanina

Caccavari

Norman

J.C.

Humphries

M.J.

Bussolino

Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells

PLoS Biol. 2009 7 e25

10.1371/journal.pbio.1000025

21.

Margadant

Monsuur

H.N.

Norman

J.C.

Sonnenberg

Mechanisms of integrin activation and trafficking

Curr. Opin. Cell Biol. 2011 23 607 614

10.1016/j.ceb.2011.08.005

22.

Lobert

V.H.

Brech

Pedersen

N.M.

Wesche

Oppelt

Malerod

Stenmark

Ubiquitination of alpha 5 beta 1 integrin controls fibroblast migration through lysosomal degradation of fibronectin-integrin complexes

Dev. Cell 2010 19 148 159

10.1016/j.devcel.2010.06.010

23.

Shi

Sottile

Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnover

J. Cell. Sci. 2008 121 2360 2371

10.1242/jcs.014977

24.

Pellinen

Arjonen

Vuoriluoto

Kallio

Fransen

J.A.

Ivaska

Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of beta1-integrins

J. Cell Biol. 2006 173 767 780

10.1083/jcb.200509019

25.

Caswell

P.T.

Chan

Lindsay

A.J.

McCaffrey

M.W.

Boettiger

Norman

J.C.

Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments

J. Cell Biol. 2008 183 143 155

10.1083/jcb.200804140

26.

Bridgewater

R.E.

Norman

J.C.

Caswell

P.T.

Integrin trafficking at a glance

J. Cell. Sci. 2012 125 3695 3701

10.1242/jcs.095810

23027580

27.

Caswell

P.T.

Spence

H.J.

Parsons

White

D.P.

Clark

Cheng

K.W.

Mills

G.B.

Humphries

M.J.

Messent

A.J.

Anderson

K.I.

Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments

Dev. Cell 2007 13 496 510

10.1016/j.devcel.2007.08.012

28.

Schwartz

M.A.

Integrins and extracellular matrix in mechanotransduction

Cold Spring Harb. Perspect. Biol. 2010 2 a005066

10.1101/cshperspect.a005066

29.

Roca-Cusachs

Iskratsch

Sheetz

M.P.

Finding the weakest link: Exploring integrin-mediated mechanical molecular pathways

J. Cell. Sci. 2012 125 3025 3038

10.1242/jcs.095794

30.

Roca-Cusachs

Gauthier

N.C.

Del Rio

Sheetz

M.P.

Clustering of alpha(5)beta(1) integrins determines adhesion strength whereas alpha(v)beta(3) and talin enable mechanotransduction

Proc. Natl. Acad. Sci. USA 2009 106 16245 16250

10.1073/pnas.0902818106

19805288

31.

Friedland

J.C.

Lee

M.H.

Boettiger

Mechanically activated integrin switch controls alpha5beta1 function

Science 2009 323 642 644

10.1126/science.1168441

32.

Mierke

C.T.

Frey

Fellner

Herrmann

Fabry

Integrin alpha5beta1 facilitates cancer cell invasion through enhanced contractile forces

J. Cell. Sci. 2011 124 369 383

10.1242/jcs.071985

33.

Menon

Beningo

K.A.

Cancer cell invasion is enhanced by applied mechanical stimulation

PLoS One 2011 6 e17277

10.1371/journal.pone.0017277

21359145

34.

Yang

J.T.

Rayburn

Hynes

R.O.

Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development

Development 1995 121 549 560

7539359

35.

Bader

B.L.

Rayburn

Crowley

Hynes

R.O.

Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins

Cell 1998 95 507 519

10.1016/S0092-8674(00)81618-9

36.

Carlson

T.R.

Braren

Kim

Y.H.

Wang

R.A.

Cell-autonomous requirement for beta1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice

Development 2008 135 2193 2202

10.1242/dev.016378

37.

Yang

J.T.

Rayburn

Hynes

R.O.

Embryonic mesodermal defects in alpha 5 integrin-deficient mice

Development 1993 119 1093 1105

7508365

38.

Goh

K.L.

Yang

J.T.

Hynes

R.O.

Mesodermal defects and cranial neural crest apoptosis in alpha5 integrin-null embryos

Development 1997 124 4309 4319

9334279

39.

George

E.L.

Georges-Labouesse

E.N.

Patel-King

R.S.

Rayburn

Hynes

R.O.

Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin

Development 1993 119 1079 1091

8306876

40.

Van der Flier

Badu-Nkansah

Whittaker

C.A.

Crowley

Bronson

R.T.

Lacy-Hulbert

Hynes

R.O.

Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development

Development 2010 137 2439 2449

10.1242/dev.049551

20570943

41.

Welser-Alves

van der Flier

Boroujerdi

Hynes

R.O.

Milner

An angiogenic role for the alpha5beta1 integrin in promoting endothelial cell proliferation during cerebral hypoxia

Exp. Neurol. 2012 237 46 54

10.1016/j.expneurol.2012.06.005

42.

Sudhakar

Sugimoto

Yang

Lively

Zeisberg

Kalluri

Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins

Proc. Natl. Acad. Sci. USA 2003 100 4766 4771

10.1073/pnas.0730882100

43.

Orecchia

Lacal

P.M.

Schietroma

Morea

Zambruno

Failla

C.M.

Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin

J. Cell. Sci. 2003 116 3479 3489

10.1242/jcs.00673

44.

Felcht

Luck

Schering

Seidel

Srivastava

Bartol

Kienast

Vettel

Loos

E.K.

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

J. Clin. Invest. 2012 122 1991 2005

10.1172/JCI58832

22585576

45.

Kim

Bell

Mousa

S.A.

Varner

J.A.

Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin

Am. J. Pathol. 2000 156 1345 1362

10.1016/S0002-9440(10)65005-5

46.

Magnussen

Kasman

I.M.

Norberg

Baluk

Murray

McDonald

D.M.

Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels

Cancer Res. 2005 65 2712 2721

10.1158/0008-5472.CAN-04-2691

15805270

47.

Zhang

Baciu

P.C.

Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis

Invest. Ophthalmol. Vis. Sci. 2002 43 955 962

11923234

48.

Bussolati

Deambrosis

Russo

Deregibus

M.C.

Camussi

Altered angiogenesis and survival in human tumor-derived endothelial cells

FASEB J. 2003 17 1159 1161

12709414

49.

Parsons-Wingerter

Kasman

I.M.

Norberg

Magnussen

Zanivan

Rissone

Baluk

Favre

C.J.

Jeffry

Murray

Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors

Am. J. Pathol. 2005 167 193 211

10.1016/S0002-9440(10)62965-3

50.

Klein

de Fougerolles

A.R.

Blaikie

Khan

Pepe

Green

C.D.

Koteliansky

Giancotti

F.G.

Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation

Mol. Cell. Biol. 2002 22 5912 5922

10.1128/MCB.22.16.5912-5922.2002

12138201

51.

Kim

Bakre

Yin

Varner

J.A.

Inhibition of endothelial cell survival and angiogenesis by protein kinase A

J. Clin. Invest. 2002 110 933 941

12370271

52.

Stupack

D.G.

Puente

X.S.

Boutsaboualoy

Storgard

C.M.

Cheresh

D.A.

Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins

J. Cell. Biol. 2001 155 459 470

10.1083/jcb.200106070

53.

Bhaskar

Zhang

Fox

Seto

Wong

M.H.

Wales

P.E.

Powers

Chao

D.T.

Dubridge

R.B.

Ramakrishnan

A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo

J. Transl. Med. 2007 5 61

10.1186/1479-5876-5-61

54.

Varner

J.A.

Emerson

D.A.

Juliano

R.L.

Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin

Mol. Biol. Cell. 1995 6 725 740

7579691

55.

O'Brien

Frisch

S.M.

Juliano

R.L.

Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation

Exp. Cell. Res. 1996 224 208 213

10.1006/excr.1996.0130

56.

Schmidt

Streit

Kaiser

Herzberg

Schirner

Schramm

Kaufmann

Henneken

Schafer-Korting

Thiel

De novo expression of the alpha5beta1-fibronectin receptor in HT29 colon-cancer cells reduces activity of C-SRC. Increase of C-SRC activity by attachment on fibronectin

Int. J. Cancer 1998 76 91 98

10.1002/(SICI)1097-0215(19980330)76:1<91::AID-IJC15>3.0.CO;2-J

57.

Schirner

Herzberg

Schmidt

Streit

Schoning

Hummel

Kaufmann

Thiel

Kreuser

E.D.

Integrin alpha5beta1: A potent inhibitor of experimental lung metastasis

Clin. Exp. Metastasis 1998 16 427 435

10091938

58.

Chantret

Barbat

Dussaulx

Brattain

M.G.

Zweibaum

Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: A survey of twenty cell lines

Cancer Res. 1988 48 1936 1942

3349466

59.

Gong

Wang

Sun

Zborowska

Willson

J.K.

Brattain

M.G.

Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells

Cell Growth Differ. 1997 8 83 90

8993837

60.

Murillo

C.A.

Rychahou

P.G.

Evers

B.M.

Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers

Surgery 2004 136 143 149

10.1016/j.surg.2004.04.006

61.

Toquet

Colson

Jarry

Bezieau

Volteau

Boisseau

Merlin

Laboisse

C.L.

Mosnier

J.F.

ADAM15 to alpha5beta1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis

Int. J. Cancer 2012 130 278 287

10.1002/ijc.25891

21190186

62.

Koike

Kimura

Miyazaki

Yabuta

Kumamoto

Takenoshita

Chen

Kobayashi

Hosokawa

Taniguchi

Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates

Proc. Natl. Acad. Sci. USA 2004 101 8132 8137

10.1073/pnas.0402088101

15141079

63.

Anderson

J.A.

Grabowska

A.M.

Watson

S.A.

PTHrP increases transcriptional activity of the integrin subunit alpha5

Br. J. Cancer 2007 96 1394 1403

17406357

64.

Nam

E.H.

Lee

Park

Y.K.

Lee

J.W.

Kim

ZEB2 upregulates integrin alpha5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells

Carcinogenesis 2012 33 563 571

10.1093/carcin/bgs005

65.

Reyes-Reyes

M.E.

George

M.D.

Roberts

J.D.

Akiyama

S.K.

P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin

Exp. Cell. Res. 2006 312 4056 4069

10.1016/j.yexcr.2006.09.008

66.

Camacho-Leal

Zhai

A.B.

Stanners

C.P.

A co-clustering model involving alpha5beta1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA)

J. Cell. Physiol. 2007 211 791 802

10.1002/jcp.20989

67.

Dia

V.P.

Mejia

E.G.

Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression

Cancer Lett. 2011 295 44 53 68.

Shibata

Kikkawa

Nawa

Suganuma

Hamaguchi

Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines

Cancer Res. 1997 57 5416 5420

9393769

69.

Casey

R.C.

Burleson

K.M.

Skubitz

K.M.

Pambuccian

S.E.

Oegema

T.R.

Jr. Ruff

L.E.

Skubitz

A.P.

Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids

Am. J. Pathol. 2001 159 2071 2080

10.1016/S0002-9440(10)63058-1

70.

Burleson

K.M.

Casey

R.C.

Skubitz

K.M.

Pambuccian

S.E.

Oegema

T.R.

Jr. Skubitz

A.P.

Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers

Gynecol. Oncol. 2004 93 170 181

10.1016/j.ygyno.2003.12.034

71.

Yokoyama

Ramakrishnan

Binding of endostatin to human ovarian cancer cells inhibits cell attachment

Int. J. Cancer 2007 121 2402 2409

10.1002/ijc.22935

72.

Yokoyama

Sedgewick

Ramakrishnan

Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination

Cancer Res. 2007 67 10813 10822

10.1158/0008-5472.CAN-07-0172

73.

Dong

Tan

O.L.

Loessner

Stephens

Walpole

Boyle

G.M.

Parsons

P.G.

Clements

J.A.

Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma

Cancer Res. 2010 70 2624 2633

10.1158/0008-5472.CAN-09-3415

74.

Sawada

Mitra

A.K.

Radjabi

A.R.

Bhaskar

Kistner

E.O.

Tretiakova

Jagadeeswaran

Montag

Becker

Kenny

H.A.

Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target

Cancer Res. 2008 68 2329 2339

10.1158/0008-5472.CAN-07-5167

18381440

75.

Liu

Lin

Yan

Wang

Zhang

Expression and correlation of Lewis y antigen and integrins alpha5 and beta1 in ovarian serous and mucinous carcinoma

Int. J. Gynecol. Cancer 2010 20 1482 1489

21119363

76.

Mitra

A.K.

Sawada

Tiwari

Mui

Gwin

Lengyel

Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis

Oncogene 2011 30 1566 1576

10.1038/onc.2010.532

77.

Deng

Zhang

Miao

Han

Zhang

Wen

Zhang

Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin alpha5beta1 and phosphorylating FAK and paxillin

J. Exp. Clin. Cancer Res. 2012 31 19

10.1186/1756-9966-31-19

78.

Sawada

Ohyagi-Hara

Kimura

Morishige

Integrin inhibitors as a therapeutic agent for ovarian cancer

J. Oncol. 2012 2012 915140

22235205

79.

Seftor

R.E.

Seftor

E.A.

Sheng

Pemberton

P.A.

Sager

Hendrix

M.J.

Maspin suppresses the invasive phenotype of human breast carcinoma

Cancer Res. 1998 58 5681 5685

9865722

80.

Ignatoski

K.M.

Maehama

Markwart

S.M.

Dixon

J.E.

Livant

D.L.

Ethier

S.P.

ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells

Br. J. Cancer 2000 82 666 674

10.1054/bjoc.1999.0979

81.

Jia

Zeng

Z.Z.

Markwart

S.M.

Rockwood

K.F.

Ignatoski

K.M.

Ethier

S.P.

Livant

D.L.

Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells

Cancer Res. 2004 64 8674 8681

10.1158/0008-5472.CAN-04-0069

15574776

82.

Maschler

Wirl

Spring

Bredow

D.V.

Sordat

Beug

Reichmann

Tumor cell invasiveness correlates with changes in integrin expression and localization

Oncogene 2005 24 2032 2041

10.1038/sj.onc.1208423

83.

Spangenberg

Lausch

E.U.

Trost

T.M.

Prawitt

May

Keppler

Fees

S.A.

Reutzel

Bell

Schmitt

ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions

Cancer Res. 2006 66 3715 3725

10.1158/0008-5472.CAN-05-2823

16585198

84.

Qin

Chen

Feng

Wang

Liao

Steroid receptor coactivator-1 upregulates integrin alpha(5) expression to promote breast cancer cell adhesion and migration

Cancer Res. 2011 71 1742 1751

10.1158/0008-5472.CAN-10-3453

21343398

85.

Baranwal

Wang

Rathinam

Lee

Jin

McGoey

Pylayeva

Giancotti

Blobe

G.C.

Alahari

S.K.

Molecular characterization of the tumor-suppressive function of nischarin in breast cancer

J. Natl. Cancer Inst. 2011 103 1513 1528

10.1093/jnci/djr350

86.

Wong

A.W.

Paulson

Q.X.

Hong

Stubbins

R.E.

Poh

Schrader

Nunez

N.P.

Alcohol promotes breast cancer cell invasion by regulating the Nm23-ITGA5 pathway

J. Exp. Clin. Cancer Res. 2011 30 75

10.1186/1756-9966-30-75

87.

Liang

Y.L.

Jin

Zhang

Duan

Zha

Positive expression of E-cadherin suppresses cell adhesion to fibronectin via reduction of alpha5beta1 integrin in human breast carcinoma cells

J. Cancer Res. Clin. Oncol. 2006 132 795 803

10.1007/s00432-006-0128-2

88.

Imanishi

Jarzynka

M.J.

Guo

Elishaev

Bar-Joseph

Cheng

S.Y.

Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway

Cancer Res. 2007 67 4254 4263

10.1158/0008-5472.CAN-06-4100

17483337

89.

Morozevich

Kozlova

Cheglakov

Ushakova

Berman

Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity

Cell Cycle 2009 8 2219 2225

10.4161/cc.8.14.8980

19617714

90.

Baranwal

Wang

Rathinam

Lee

Jin

McGoey

Pylayeva

Giancotti

Blobe

G.C.

Alahari

S.K.

Molecular characterization of the tumor-suppressive function of nischarin in breast cancer

J. Natl. Cancer Inst. 2011 103 1513 1528

10.1093/jnci/djr350

91.

Nam

J.M.

Onodera

Bissell

M.J.

Park

C.C.

Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin

Cancer Res. 2010 70 5238 5248

10.1158/0008-5472.CAN-09-2319

92.

Mythreye

Knelson

E.H.

Gatza

C.E.

Gatza

M.L.

Blobe

G.C.

TbetaRIII/beta-arrestin2 regulates integrin alpha5beta1 trafficking, function, and localization in epithelial cells

Oncogene 2012

10.1038/onc.2012.157

93.

Wang

Shenouda

Baranwal

Rathinam

Jain

Bao

Hazari

Dash

Alahari

S.K.

Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis

Mol. Cancer 2011 10 84

10.1186/1476-4598-10-84

94.

Dingemans

A.M.

van den Boogaart

Vosse

B.A.

van Suylen

R.J.

Griffioen

A.W.

Thijssen

V.L.

Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer

Mol. Cancer 2010 9 152

10.1186/1476-4598-9-152

95.

Adachi

Taki

Higashiyama

Kohno

Inufusa

Miyake

Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer

Clin. Cancer Res. 2000 6 96 101

10656437

96.

Han

J.Y.

Kim

H.S.

Lee

S.H.

Park

W.S.

Lee

J.Y.

Yoo

N.J.

Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: Correlation with lymph node metastasis

Lung Cancer 2003 41 65 70

10.1016/S0169-5002(03)00146-6

12826314

97.

Lawson

M.H.

Cummings

N.M.

Rassl

D.M.

Vowler

S.L.

Wickens

Howat

W.J.

Brenton

J.D.

Murphy

Rintoul

R.C.

Bcl-2 and beta1-integrin predict survival in a tissue microarray of small cell lung cancer

Br. J. Cancer 2010 103 1710 1715

10.1038/sj.bjc.6605950

98.

Roman

Ritzenthaler

J.D.

Roser-Page

Sun

Han

alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer

Am. J. Respir. Cell Mol. Biol. 2010 43 684 691

10.1165/rcmb.2009-0375OC

99.

Han

Khuri

F.R.

Roman

Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways

Cancer Res. 2006 66 315 323

10.1158/0008-5472.CAN-05-2367

100.

Ritzenthaler

J.D.

Han

Roman

Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling

Mol. Biosyst. 2008 4 1160 1169

10.1039/b800533h

101.

Caccavari

Valdembri

Sandri

Bussolino

Serini

Integrin signaling and lung cancer

Cell Adh. Migr. 2009 4 124 129 102.

Sethi

Rintoul

R.C.

Moore

S.M.

MacKinnon

A.C.

Salter

Choo

Chilvers

E.R.

Dransfield

Donnelly

S.C.

Strieter

Haslett

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo

Nat. Med. 1999 5 662 628

10.1038/9511

10371505

103.

Rintoul

R.C.

Sethi

Extracellular matrix regulation of drug resistance in small-cell lung cancer

Clin. Sci. (Lond.) 2002 102 417 424

10.1042/CS20010216

104.

Buttery

R.C.

Rintoul

R.C.

Sethi

Small cell lung cancer: The importance of the extracellular matrix

Int. J. Biochem. Cell Biol. 2004 36 1154 1160

10.1016/S1357-2725(03)00261-9

105.

Hodkinson

P.S.

Elliott

Wong

W.S.

Rintoul

R.C.

Mackinnon

A.C.

Haslett

Sethi

ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase

Cell Death Differ. 2006 13 1776 1788

10.1038/sj.cdd.4401849

106.

Gingras

M.C.

Roussel

Bruner

J.M.

Branch

C.D.

Moser

R.P.

Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue

J. Neuroimmunol. 1995 57 143 153

10.1016/0165-5728(94)00178-Q

107.

Riemenschneider

M.J.

Mueller

Betensky

R.A.

Mohapatra

Louis

D.N.

In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation

Am. J. Pathol. 2005 167 1379 1387

10.1016/S0002-9440(10)61225-4

108.

Kita

Takino

Nakada

Takahashi

Yamashita

Sato

Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line

Cancer Res. 2001 61 7985 7991

11691823

109.

Janouskova

Maglott

Leger

D.Y.

Bossert

Noulet

Guerin

Guenot

Pinel

Chastagner

Plenat

Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma

Cancer Res. 2012 72 3463 3470

10.1158/0008-5472.CAN-11-4199

22593187

110.

Cosset

E.C.

Godet

Entz-Werle

Guerin

Guenot

Froelich

Bonnet

Pinel

Plenat

Chastagner

Involvement of the TGFbeta pathway in the regulation of alpha5 beta1 integrins by caveolin-1 in human glioblastoma

Int. J. Cancer 2012 131 601 611

10.1002/ijc.26415

21901744

111.

Holmes

K.M.

Annala

Chua

C.Y.

Dunlap

S.M.

Liu

Hugen

Moore

L.M.

Cogdell

Nykter

Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network

Proc. Natl. Acad. Sci. USA 2012 109 3475 3480

10.1073/pnas.1120375109

22345562

112.

Martin

Cosset

E.C.

Terrand

Maglott

Takeda

Dontenwill

Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist

Biochim. Biophys. Acta 2009 1793 354 367

10.1016/j.bbamcr.2008.09.019

113.

Martinkova

Maglott

Leger

D.Y.

Bonnet

Stiborova

Takeda

Martin

Dontenwill

alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells

Int. J. Cancer 2010 127 1240 1248

10.1002/ijc.25187

114.

Maglott

Bartik

Cosgun

Klotz

Ronde

Fuhrmann

Takeda

Martin

Dontenwill

The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells

Cancer Res. 2006 66 6002 6007

10.1158/0008-5472.CAN-05-4105

115.

Kesanakurti

Chetty

Dinh

D.H.

Gujrati

Rao

J.S.

Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha5beta1 integrin in glioma

Oncogene 2012

10.1038/onc.2012.52

116.

Chahal

Abdulkarim

Guiot

M.C.

Easaw

J.C.

Stifani

Sabri

O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme

Mol. Cancer Ther. 2012 11 2440 2450

10.1158/1535-7163.MCT-11-0977

117.

Qian

Zhang

Z.C.

X.F.

Y.P.

Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells

Biochem. Biophys. Res. Commun. 2005 333 1269 1275

10.1016/j.bbrc.2005.06.039

118.

McKenzie

J.A.

Liu

Goodson

A.G.

Grossman

Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation

Cancer Res. 2010 70 7927 7937

10.1158/0008-5472.CAN-10-0194

119.

Arpaia

Blaser

Quintela-Fandino

Duncan

Leong

H.S.

Ablack

Nambiar

S.C.

Lind

E.F.

Silvester

Fleming

C.K.

The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk

Oncogene 2012 31 884 896

10.1038/onc.2011.288

120.

Beliveau

Berube

Rousseau

Pelletier

Guerin

S.L.

Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma

Invest. Ophthalmol. Vis. Sci. 2000 41 2363 2372

10892885

121.

Beliveau

Berube

Carrier

Mercier

Guerin

S.L.

Tumorigenicity of the mixed spindle-epithelioid SP6. 5 and epithelioid TP17 uveal melanoma cell lines is differentially related to alpha5beta1 integrin expression

Invest. Ophthalmol. Vis. Sci. 2001 42 3058 3065

11687555

122.

Landreville

Vigneault

Bergeron

M.A.

Leclerc

Gaudreault

Morcos

Mouriaux

Salesse

Guerin

S.L.

Suppression of alpha5 gene expression is closely related to the tumorigenic properties of uveal melanoma cell lines

Pigment. Cell Melanoma Res. 2011 24 643 655

10.1111/j.1755-148X.2011.00869.x

123.

Ramakrishnan

Bhaskar

Law

D.A.

Wong

M.H.

DuBridge

R.B.

Breinberg

O'Hara

Powers

D.B.

Liu

Grove

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent

J. Exp. Ther. Oncol. 2006 5 273 286

17024968

124.

Bhaskar

Fox

Breinberg

Wong

M.H.

Wales

P.E.

Rhodes

DuBridge

R.B.

Ramakrishnan

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

Invest. New Drugs 2008 26 7 12

10.1007/s10637-007-9078-z

125.

Almokadem

Belani

C.P.

Volociximab in cancer

Expert Opin. Biol. Ther. 2011 12 251 257

10.1517/14712598.2012.646985

126.

Besse

Tsao

L.C.

Chao

D.T.

Fang

Soria

J.C.

Almokadem

Belani

C.P.

Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

Ann. Oncol. 2012

10.1093/annonc/mds281

127.

Ricart

A.D.

Tolcher

A.W.

Liu

Holen

Schwartz

Albertini

Weiss

Yazji

Wilding

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study

Clin. Cancer Res. 2008 14 7924 7929

10.1158/1078-0432.CCR-08-0378

19047123

128.

Bell-McGuinn

K.M.

Matthews

C.M.

S.N.

Barve

Gilbert

Penson

R.T.

Lengyel

Palaparthy

Gilder

Vassos

A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

Gynecol. Oncol. 2011 121 273 279

10.1016/j.ygyno.2010.12.362

129.

Yazji

Bukowski

Kondagunta

Figlin

Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)

J. Clin. Oncol. 2007 25 Abstract 5094. 130.

Zhang

Chen

Wang

Jiang

Chen

J.H.

Wickman

Amundson

Bergqvist

Zobel

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity

Cancer Res. 2010 70 10243 10254

10.1158/0008-5472.CAN-10-1996

21159645

131.

Smallheer

J.M.

Weigelt

C.A.

Woerner

F.J.

Wells

J.S.

Daneker

W.F.

Mousa

S.A.

Wexler

R.R.

Jadhav

P.K.

Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds

Bioorg. Med. Chem. Lett. 2004 14 383 387

10.1016/j.bmcl.2003.10.057

14698164

132.

Marinelli

Meyer

Heckmann

Lavecchia

Novellino

Kessler

Ligand binding analysis for human alpha5beta1 integrin: Strategies for designing new alpha5beta1 integrin antagonists

J. Med. Chem. 2005 48 4204 4207

10.1021/jm040224i

133.

Heckmann

Meyer

Marinelli

Zahn

Stragies

Kessler

Probing integrin selectivity: Rational design of highly active and selective ligands for the alpha5beta1 and alphavbeta3 integrin receptor

Angew. Chem. Int. Ed. Engl. 2007 46 3571 3574

10.1002/anie.200700008

17394271

134.

Heckmann

Meyer

Laufer

Zahn

Stragies

Kessler

Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor

Chembiochem 2008 9 1397 1407

10.1002/cbic.200800045

135.

Meyer

Auernheimer

Modlinger

Kessler

Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting

Curr. Pharm. Des. 2006 12 2723 2747

10.2174/138161206777947740

136.

Stragies

Osterkamp

Zischinsky

Vossmeyer

Kalkhof

Reimer

Zahn

Design and synthesis of a new class of selective integrin alpha5beta1 antagonists

J. Med. Chem. 2007 50 3786 3794

10.1021/jm070002v

137.

Umeda

Kachi

Akiyama

Zahn

Vossmeyer

Stragies

Campochiaro

P.A.

Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist

Mol. Pharmacol. 2006 69 1820 1828

10.1124/mol.105.020941

138.

Muether

P.S.

Dell

Kociok

Zahn

Stragies

Vossmeyer

Joussen

A.M.

The role of integrin alpha5beta1 in the regulation of corneal neovascularization

Exp. Eye Res. 2007 85 356 365

10.1016/j.exer.2007.06.004

139.

Zahn

Vossmeyer

Stragies

Wills

Wong

C.G.

Loffler

K.U.

Adamis

A.P.

Knolle

Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization

Arch. Ophthalmol. 2009 127 1329 1335

10.1001/archophthalmol.2009.265

140.

Zahn

Volk

Lewis

G.P.

Vossmeyer

Stragies

Heier

J.S.

Daniel

P.E.

Jr. Adamis

A.P.

Chapin

E.A.

Fisher

S.K.

Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment

Invest. Ophthalmol. Vis. Sci. 2010 51 1028 1035

10.1167/iovs.09-3575

141.

Okazaki

Ayeni

O.A.

Baluk

Yao

L.C.

Vossmeyer

Zischinsky

Zahn

Knolle

Christner

McDonald

D.M.

alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation

Am. J. Pathol. 2009 174 2378 2387

10.2353/ajpath.2009.080942

142.

Zischinsky

Osterkamp

Vossmeyer

Zahn

Scharn

Zwintscher

Stragies

SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists

Bioorg. Med. Chem. Lett. 2010 20 65 68

10.1016/j.bmcl.2009.11.030

19959360

143.

Zischinsky

Osterkamp

Vossmeyer

Zahn

Scharn

Zwintscher

Stragies

Discovery of orally available integrin alpha5beta1 antagonists

Bioorg. Med. Chem. Lett. 2010 20 380 382

10.1016/j.bmcl.2009.10.073

144.

Delouvrie

Al-Kadhimi

Arnould

J.C.

Barry

S.T.

Cross

D.A.

Didelot

Gavine

P.R.

Germain

Harris

C.S.

Hughes

A.M.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting alpha5beta1: Part 1

Bioorg. Med. Chem. Lett. 2012 22 4111 4116

10.1016/j.bmcl.2012.04.063

22575869

145.

Delouvrie

Al-Kadhimi

Arnould

J.C.

Barry

S.T.

Cross

D.A.

Didelot

Gavine

P.R.

Germain

Harris

C.S.

Hughes

A.M.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting alpha5beta1: Part 2

Bioorg. Med. Chem. Lett. 2012 22 4117 4121

10.1016/j.bmcl.2012.04.061

22572578

146.

Livant

D.L.

Brabec

R.K.

Pienta

K.J.

Allen

D.L.

Kurachi

Markwart

Upadhyaya

Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma

Cancer Res. 2000 60 309 320

10667582

147.

Livant

D.L.

Brabec

R.K.

Kurachi

Allen

D.L.

Haaseth

Andrews

Ethier

S.P.

Markwart

The PHSRN sequence induces extracellular matrix invasion and accelerates wound healing in obese diabetic mice

J. Clin. Invest. 2000 105 1537 1545

10.1172/JCI8527

148.

Zeng

Z.Z.

Yao

Staszewski

E.D.

Rockwood

K.F.

Markwart

S.M.

Fay

K.S.

Spalding

A.C.

Livant

D.L.

alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate Angiogenesis

Transl. Oncol. 2009 2 8 20

19252747

149.

Van Golen

K.L.

Bao

Brewer

G.J.

Pienta

K.J.

Kamradt

J.M.

Livant

D.L.

Merajver

S.D.

Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma

Neoplasia 2002 4 373 379

10.1038/sj.neo.7900258

150.

Stoeltzing

Liu

Reinmuth

Fan

Parry

G.C.

Parikh

A.A.

McCarty

M.F.

Bucana

C.D.

Mazar

A.P.

Ellis

L.M.

Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice

Int. J. Cancer 2003 104 496 503

10.1002/ijc.10958

151.

Khalili

Arakelian

Chen

Plunkett

M.L.

Beck

Parry

G.C.

Donate

Shaw

D.E.

Mazar

A.P.

Rabbani

S.A.

A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo

Mol. Cancer Ther. 2006 5 2271 2280

10.1158/1535-7163.MCT-06-0100

152.

Wang

Huang

Sun

The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo

Invest. Ophthalmol. Vis. Sci. 2011 52 7213 7220

10.1167/iovs.10-7097

153.

Cianfrocca

M.E.

Kimmel

K.A.

Gallo

Cardoso

Brown

M.M.

Hudes

Lewis

Weiner

Lam

G.N.

Brown

S.C.

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours

Br. J. Cancer 2006 94 1621 1626

16705310

154.

Yao

Veine

D.M.

Zeng

Z.Z.

Fay

K.S.

Staszewski

E.D.

Livant

D.L.

Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation

Clin. Exp. Metastasis 2010 27 173 184

10.1007/s10585-010-9316-1

155.

Yao

Veine

D.M.

Fay

K.S.

Staszewski

E.D.

Zeng

Z.Z.

Livant

D.L.

The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation

Breast Cancer Res. Treat. 2011 125 363 175

10.1007/s10549-010-0826-y

20300829